Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65

PHASE2CompletedINTERVENTIONAL
Enrollment

1,044

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

September 30, 2015

Conditions
Tuberculosis
Interventions
BIOLOGICAL

5μg/ml ESAT6-CFP10

The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .

BIOLOGICAL

10μg/ml ESAT6-CFP10

The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .

BIOLOGICAL

BCG

The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

BIOLOGICAL

placebo

The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

Trial Locations (1)

Unknown

Jurong Province Centers for Disease Control and Prevention, Jurong

All Listed Sponsors
collaborator

Air Force Military Medical University, China

OTHER

collaborator

Proswell Medical Corporation

INDUSTRY

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

collaborator

Jurong Province Centers for Disease Control and Prevention

OTHER

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT02389322 - Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65 | Biotech Hunter | Biotech Hunter